Swiss National Bank’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.43M | Buy |
176,096
+4,800
| +3% | +$119K | ﹤0.01% | 1402 |
|
|
2026
Q1 | $3.7M | Buy |
171,296
+3,300
| +2% | +$71.3K | ﹤0.01% | 1519 |
|
|
2025
Q4 | $4M | Buy |
167,996
+34,500
| +26% | +$704K | ﹤0.01% | 1481 |
|
|
2025
Q3 | $1.82M | Buy |
133,496
+12,200
| +10% | +$127K | ﹤0.01% | 1908 |
|
|
2025
Q2 | $987K | Sell |
121,296
-12,300
| -9% | -$105K | ﹤0.01% | 2151 |
|
|
2025
Q1 | $1.05M | Buy |
133,596
+35,300
| +36% | +$409K | ﹤0.01% | 2108 |
|
|
2024
Q4 | $1.46M | Hold |
98,296
| – | – | ﹤0.01% | 2032 |
|
|
2024
Q3 | $1.5M | Hold |
98,296
| – | – | ﹤0.01% | 2010 |
|
|
2024
Q2 | $1.5M | Buy |
98,296
+2,900
| +3% | +$46.8K | ﹤0.01% | 1958 |
|
|
2024
Q1 | $1.8M | Hold |
95,396
| – | – | ﹤0.01% | 1893 |
|
|
2023
Q4 | $1.82M | Sell |
95,396
-9,000
| -9% | -$144K | ﹤0.01% | 1900 |
|
|
2023
Q3 | $1.87M | Buy |
104,396
+9,100
| +10% | +$183K | ﹤0.01% | 1881 |
|
|
2023
Q2 | $1.94M | Buy |
95,296
+1,600
| +2% | +$30.5K | ﹤0.01% | 1913 |
|
|
2023
Q1 | $1.71M | Sell |
93,696
-10,800
| -10% | -$206K | ﹤0.01% | 1938 |
|
|
2022
Q4 | $2.16M | Buy |
104,496
+2,500
| +2% | +$68.8K | ﹤0.01% | 1850 |
|
|
2022
Q3 | $2.67M | Buy |
101,996
+1,500
| +1% | +$39.7K | ﹤0.01% | 1675 |
|
|
2022
Q2 | $2.55M | Buy |
100,496
+9,200
| +10% | +$225K | ﹤0.01% | 1749 |
|
|
2022
Q1 | $2.88M | Buy |
91,296
+4,800
| +6% | +$161K | ﹤0.01% | 1812 |
|
|
2021
Q4 | $3.5M | Buy |
86,496
+600
| +0.7% | +$23.3K | ﹤0.01% | 1698 |
|
|
2021
Q3 | $3M | Hold |
85,896
| – | – | ﹤0.01% | 1786 |
|
|
2021
Q2 | $2.36M | Sell |
85,896
-10,600
| -11% | -$303K | ﹤0.01% | 1999 |
|
|
2021
Q1 | $2.71M | Buy |
96,496
+1,100
| +1% | +$38.3K | ﹤0.01% | 1828 |
|
|
2020
Q4 | $2.48M | Buy |
95,396
+11,600
| +14% | +$281K | ﹤0.01% | 1787 |
|
|
2020
Q3 | $1.44M | Buy |
83,796
+1,300
| +2% | +$29K | ﹤0.01% | 1885 |
|
|
2020
Q2 | $2.04M | Buy |
82,496
+37,996
| +85% | +$1.03M | ﹤0.01% | 1702 |
|
|
2020
Q1 | $618K | Buy |
44,500
+1,300
| +3% | +$16.2K | ﹤0.01% | 2084 |
|
|
2019
Q4 | $436K | Hold |
43,200
| – | – | ﹤0.01% | 2449 |
|
|
2019
Q3 | $393K | Hold |
43,200
| – | – | ﹤0.01% | 2419 |
|
|
2019
Q2 | $343K | Hold |
43,200
| – | – | ﹤0.01% | 2496 |
|
|
2019
Q1 | $540K | Hold |
43,200
| – | – | ﹤0.01% | 2351 |
|
|
2018
Q4 | $465K | Buy |
+43,200
| New | +$504K | ﹤0.01% | 2378 |
|
Other funds holding RCUS
GS
SCM
WP
Swiss National Bank's RCUS Position: Q2 2026 in Review
Swiss National Bank increased its Arcus Biosciences (RCUS) stake by 2.8% in Q2 2026, buying an estimated $119K and bringing the position to 176,096 shares worth $5.43M. The position accounts for ﹤0.01% of the portfolio, ranked #1402.
Swiss National Bank first reported a position in RCUS in Q4 2018 and has held it in 31 quarters since. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.
- Swiss National Bank held 176,096 shares of Arcus Biosciences worth $5.43M as of Q2 2026.
- Swiss National Bank bought 4,800 Arcus Biosciences shares in Q2 2026, an estimated $119K.
- Arcus Biosciences made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #1402 holding.
- Swiss National Bank first reported a position in Arcus Biosciences in Q4 2018 and has held it in 31 quarters since.
- 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.
Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.